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A B S T R A C T
Cutaneous tuberculosis (TB) makes up a small proportion of the 10.4 million cases around the world.
Although it is more commonly found in the developing world, cutaneous TB is rarely reported in the
developed countries. It is fairly challenging to diagnose without histological examination. In this report,
we present an immunocompetent 7-year-old male with a complex medical history diagnosed with
cutaneous Mycobacterium tuberculosis after multiple ventriculoperitoneal shunt (VPS) revisions. This
case of cutaneous TB in an immunocompetent patient is remarkable in its uncharacteristic presentation
with no obvious source of TB infected contacts or travel history.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In 2015, an estimated 10.4 million people were living with
tuberculosis (TB) across the globe [1]. TB has now surpassed HIV in
global disease-speciﬁc mortality, causing 700,000 more deaths
than HIV since the HIV pandemic started. More than 1.8 million
people worldwide died from TB in 2015, most of which have been
due to pulmonary TB and TB/HIV co-infections [2]. Nearly 10% of all
adult TB-related infections and 20% of pediatric TB cases are
extrapulmonary in nature [3,4]. Cutaneous TB makes up a small
proportion of these cases. More commonly found in the developing
world, cutaneous TB is rarely reported in the developed countries.
It is fairly challenging to diagnose without histological examina-
tion. Mycobacterium tuberculosis complex, including M. bovis and
Bacillus Calmette-Guérin are the most common causative organ-
isms. Mycobacteria are non-spore-forming, non-motile, non-toxin
producing strictly aerobic bacilli [4,5]. Factors such as individual
immunity, environmental inﬂuences, and type of inoculum are
contributory in the natural history of the disease process [4].
TB is most primarily transmitted via an airborne route, with
extrapulmonary manifestations including in the skin caused by
hematogenous or contiguous spread from a focus of infection.
However, a primary infection can occur through direct inoculation
of mycobacteria into the skin or mucosa of a susceptible individual
by trauma or injury. In the presence of HIV, intravenous drug use,
diabetes mellitus, immunosuppressive therapy, malignancy, end-
stage renal disease, or infancy, the risk of infection and disease
progression appear to be higher as compared to the immunocom-
petent individuals [6–8].
In this report, we present an immunocompetent 7-year-old
male with a complex medical history that presented with
cutaneous TB after multiple VPS revisions. The infection was
initially treated with ﬁrst-line TB therapy based on sensitivity
studies. However, after recurrent episodes, the patient had to be
maintained on prophylaxis therapy throughout the remainder of
his life.
Case Report
The patient was a Caucasian male, ex-24 week premature birth
with a medical history signiﬁcant for hydrocephalus and VPS
placement as an infant, chronic lung disease, cerebral palsy and
global developmental delay. He was home-based and had no
interactions with the outside world. At age 7, he presented to his
primary care physician with the chief complaint of an “ingrown
hair” that the mother noticed after giving him a haircut. The lesion
was noted to be pea-sized and found on the incision site of the
shunt on his scalp. The patient had no other complaints including
fever, weight loss, and acute respiratory illness. At the time, the PCP
felt no further workup was needed and sent the patient home with
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bacitracin ointment. Three days later, the lesion had grown and
begun oozing purulent ﬂuid. The patient’s mother became
concerned and her child was brought to the emergency depart-
ment (ED).
On initial presentation, the patient was noted to have erosion at
the shunt site and part of the shunt tubing could be visualized. The
patient’s neurosurgeon was contacted and he performed a shunt
revision. After an uncomplicated hospital course, the patient was
discharged home. Over the subsequent 18 months, similar
episodes occurred with the patient requiring multiple VPS
revisions.
At age 9, the patient presented to the ED with a much larger
lesion that was dime-sized. On physical examination, the patient’s
pertinent ﬁndings included an erythematous, ﬁrm, and painless
rash on the right side of the neck along the route of the shunt
catheter with a central light-colored region of granulose-like base
with oozing. He was suspected to have cellulitis as a complication
of his latest shunt revision. A bacterial culture was obtained, but
after ﬁve days there was no growth. Treatment was started with
clindamycin and bacitracin ointment for suspicion of Staphylococ-
cus aureus or beta-hemolytic streptococci.
After a 10-day course of antibacterials, symptoms persisted
with no notable improvement. Neurosurgery and infectious
disease were consulted. A biopsy of the lesion and immunological
workup was obtained. The patient was continued on the same
regimen and was started on dietary supplementation to optimize
wound healing, which included vitamin A, vitamin C, vitamin D
and zinc. The immunological workup showed normal immuno-
globulin counts, normal T and B cell subsets, and normal
neutrophils. The biopsy results showed granulomas with a
necrotizing neutrophilic inﬁltrate with numerous acid-fast bacilli
(AFB). A chest radiograph was unremarkable. A Mantoux
tuberculin skin test was performed, which showed a 17 mm
induration. Based on the ﬁndings, the patient was diagnosed with
primary cutaneous tuberculosis.
Culture studies from the biopsy were performed and grew
Mycobacterium tuberculosis. Sequencing identiﬁcation of the
pathogen by the CDC matched that of patient zero, a transient
adult male that lived in the same city and was the source of
multiple exposures. In the case of our patient, epidemiological
studies showed that he was likely exposed to TB on an ED visit
when he was 6 years old and was being seen for chronic lung
disease exacerbation.
The patient was started on isoniazid, rifampin, pyrazinamide,
and ethambutol. However, during the ﬁrst two weeks of treatment,
he began to have feeding difﬁculties and developed jaundice.
Alanine transaminase (ALT) and aspartate aminotransferase (AST)
were ﬁve times the normal range. All TB medications were stopped
until ALT and AST returned to normal. Rifampin was restarted, but
the patient again developed jaundice and elevated liver enzymes.
We determined that he could not tolerate rifampin and placed him
on double therapy of isoniazid and ethambutol for 24 months. The
patient performed well with therapy whereby there were
resolution of granulation tissue and no AFB found on post-
treatment biopsy.
Three months after the completion of treatment, the patient
underwent a VPS revision without complications during the
procedure. However, six months later, he developed a new
erythematous, non-pruritic rash with oozing at the site of incision
of the shunt revision on the scalp. A new biopsy was obtained
which showed multiple AFB, thereby resulting in his diagnosis of
recurrent cutaneous TB. Due to the hepatotoxicity of the ﬁrst
treatment plan, the patient was placed on intravenous amikacin,
oral cycloserine, and oral ethionamide for three months and
subsequently, amikacin was replaced with levaquin. The triple
therapy was maintained for 18 months with resolution of the
lesion. Given the recurrent nature of the patient’s TB, he was placed
on prophylaxis isoniazid and ethambutol with no documented
recurrence TB throughout the remainder of his life. He succumbed
from unrelated complications of his chronic disease.
Discussion
Our patient was initially diagnosed to have cellulitis due to
either Staphylococcus aureus or beta-hemolytic streptococci.
Failure of clindamycin, histologic ﬁndings on skin biopsy, and
negative bacterial cultures resulted in the diagnosis. Cutaneous
granulomas with necrotizing neutrophilic inﬁltrate with numer-
ous AFB was consistent with primary cutaneous TB (CTB).
While clinically similar, individual CTB lesions can present with
different development, progression, and prognosis. There are
commonly two well-used classiﬁcation systems (Table 1). The ﬁrst
is based on the mechanism of propagation—exogenous versus
endogenous dissemination. An exogenous propagation consists of
an infected individual inoculating a new susceptible host, while
endogenous dissemination results in a new skin inoculation from
an already infected individual. The second scheme is based on the
concept of bacterial load, which is used to differentiate between
the paucibacillary form whereby identiﬁcation of bacilli in culture
and histological tissue is very difﬁcult; and multibacillary where
the organism is easily found and identiﬁed [4].
Currently, the frequency of CTB worldwide has been variable
and according to some studies, lupus vulgaris is the most common
with 55% of all presentations, followed by scrofuloderma which is
seen in 25% of patients, and then by oriﬁcial tuberculosis,
tuberculosis verrucosa cutis, papulonecrotic tuberculid, and
erythema induratum with 5% in each [3,9,10]. However, studies
performed in Brazil, which is an endemic country for TB, show that
scrofuloderma is the most common presentation and in one
statewide retrospective study, erythema induratum of Bazin is
found to be the most common type [11,12].
There have been some individual case reports suggestive of rare
presentations of CTB. For instance, as a metastatic tuberculous
abscess, where it was presented as two distinct swellings on the
anterior chest wall that grew at different points in time. Another
rare presentation was that of a facial skin involvement with
ulceration, which was initially suspected to be a cutaneous
leishmaniasis that did not respond to standard treatment [6,7].
Table 1
Classiﬁcations for Cutaneous Tuberculosis.
Classiﬁcation I
Mechanism of Propagation Dissemination Type of Lesion
Exogenous Lupus vulgaris
Tuberculous chancre
Tuberculosis verrucosa cutis
Endogenous Contiguous Oriﬁcial tuberculosis
Scrofuloderma
Hematogenous Acute miliary tuberculosis
Lupus vulgaris
Metastatic tuberculous abscess
Papulonecrotic tuberculid
Lymphatic Lupus Vulgaris
Classiﬁcation II
Form Type of Lesion
Multibacillary Active miliary tuberculosis
Metastatic tuberculous gumma
Tuberculous chancre
Tuberculosis oriﬁcialis
Bacillary Lupus vulgaris
Tuberculids
Tuberculosis verrucosa cutis
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It has always been challenging to diagnose and promptly treat
TB due to a variety of clinical presentations, but the prescribed
guidelines for TB diagnosis have been revised to consistently
address this fundamental problem. As per the diagnostic guide-
lines quantiferon (TB GOLD), tuberculin skin test, chest X-ray and
sputum staining for AFB are used for the screening of TB. However,
recent guidelines recommend more accurate and rapid tests for TB
screening and detection as Xpert MTB/RIF, which also detects
rifampin resistance [13]. Absolute positive testing of DNA-PCR
techniques including a dry and wet culture are needed, which are
conﬁrmatory of TB [14].
As per the updatedtreatment guidelines according tothe CDCand
ISDA (2016), the aim of the treatment is to help cure the individual
patient, decrease therisk of deathand disability, reducetransmission
of Mycobacterium tuberculosis to other individuals, and prevent the
development of drug resistance. The mainstay treatment for drug-
susceptible TB, in absence of HIV infection, remains the 2-month
intensive therapy with isoniazid, rifampicin, pyrazinamide, and
ethambutol followed by four months of maintenance therapy with
isoniazid and rifampin (Table 2) [16]. It is recommended to use
directly observed therapy (DOT) for all forms of TB [13]. One of the
most common adverse events is the development of liver enzyme
elevations. In the ﬁrst two months of treatment, an asymptomatic
liver enzyme elevation can be observed in a small subset of patients
that is followed bycompletespontaneousresolutionwith no clinical
manifestations and without the need to disrupt or change the
therapeutic regimen. However, treatment should be stopped if liver
enzyme levels are greater than three times the normal value such as
in our reported case. Once liverenzyme levelsnormalize and thereis
resolution of symptoms, the reintroduction of the basic scheme is
indicated as follows: rifampin + ethambutol, followed by isoniazid
and lastly, pyrazinamide with an interval of 3–7 days between them.
If the patient again has abnormal liver enzyme levels, then an
alternate scheme for hepatic insufﬁciency must be utilized as
follows: ethambutol, streptomycin and another drug such as
isoniazid, rifampin or oﬂoxacin [15].
This case of cutaneous TB in an immunocompetent patient is
remarkable in its uncharacteristic presentation with no obvious
source of TB infected contacts or travel history. In a review of the
literature, there have been no similarly described cases in the past.
The patient likely had an unfortunate exposure while in the
emergency department where an individual with active TB
transmitted the infectious bacillus to him.
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